The story of Viagra presents a complex picture for shareholders. While the initial release generated significant gains, the lapse of its intellectual property protection opened the avenue to off-brand alternatives, https://jaysondrxv317537.rimmablog.com/40516710/the-copyright-and-big-pharma-a-volatile-opportunity